The Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 (MOMENTUM 3) and HeartMate 3 CE Mark studies recently demonstrated that HeartMate 3, a fully magnetically levitated centrifugal-flow left ventricular assist device (LVAD) (Abbott, Abbott Park, IL), 1 has a higher survival rate and a lower rate of hemocompatibility-related adverse events (HRAEs) compared to HeartMate II LVAD (Abbott, Abbott Park, IL). 2-7 Despite extremely low rates of pump thrombosis and stroke, readmissions due to decompensated heart failure (HF) and gastrointestinal bleeding remain still common. 2